PTX 2.50% 3.9¢ prescient therapeutics limited

sp should be 5x imho, page-828

  1. 595 Posts.
    lightbulb Created with Sketch. 119
    https://hotcopper.com.au/data/attachments/3367/3367199-5941149fc3c9b206b71f0c7db941dfd3.jpg
    https://hotcopper.com.au/data/attachments/3367/3367201-652979e1b215dd6032e2f941a4fe5ab4.jpg

    RAC.. different stock I know but using just for example purposes as (IMO PTX omnicar technology is out of this world.. very innovative technology) in the end this is still speculative and anything can happen. But I wonder what the people who sold at 52 cents is thinking knowing not long after the stock was sold down from 52 cents (down 50%) to booming highs confused.png

    PTX-100 was invented around 2009 by Said Sebti (Named among top 20 Translational Researchers in the world by Nature Publishing Group) and Andrew Hamilton, then a Professor of Chemistry at Yale University, now Vice Chancellor at the University of Oxford. - PTX100 safety results upcoming this quarter? (something that has been worked on by top tier blokes since 09?)

    The most significant challenge of the next decade will be to reduce the cost, (For CAR-T treatments) The list prices for the first three FDA-approved CAR T-cell therapies range from $373,000 to $475,000USD

    As the industry attempts to drive down the cost and time of delivering CAR-T therapy to patients, OmniCAR’s flexibility and control will be an increasingly valuable tool, by removing the need for multiple manufacturing runs per patient, and its compatibility with allogeneic (“off the shelf”) T-cells.

    “Many of the people who would benefit from this therapy will be unable to have it,” Shpall told Cell Therapy Next. (due to cost) https://www.healio.com/news/hematology-oncology/20201124/a-decade-of-success-cart-pioneers-reflect-on-past-look-toward-future

    Unlike conventional CAR-T, which is limited to a single target, OmniCAR-T cells are able to be armed against multiple targets sequentially or simultaneously by simply switching out the targeting ligand, which will be especially important in CAR-T making headway into the large field of solid tumours. “Solid tumors result in 90% of cancer deaths ... so that’s a great challenge now for all of oncology,”

    https://hotcopper.com.au/data/attachments/3367/3367401-d0f9d16d4213287aa659c330105d3a3d.jpg


    We have https://www.healio.com/news/hematology-oncology/20201124/a-decade-of-success-cart-pioneers-reflect-on-past-look-toward-future under challenges of the decade and our team at PTX are working at smashing these challenges. They have a strong team, if this pulls off.. I don't think words can finish off what I am about to say next BUT..

    I have came to the conclusion, I am topping up right now. GLTAH this is only my opinion

    Cheers




 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.9¢
Change
-0.001(2.50%)
Mkt cap ! $31.40M
Open High Low Value Volume
4.1¢ 4.1¢ 3.9¢ $72.73K 1.802M

Buyers (Bids)

No. Vol. Price($)
5 436541 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.1¢ 560576 1
View Market Depth
Last trade - 15.59pm 15/11/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.